Novel basal insulins and fixed-ratio combinations of basal insulin and GLP-1RA are safer and more convenient options for uncontrolled type 2 diabetes.
Pompe disease should be considered as part of the differential diagnosis for all children and adults presenting with limb-girdle muscle weakness and respiratory insufficiency1
Pompe disease (glycogen storage type II disease) is caused by a deficiency of acid alphaglucosidase (GAA) enzyme activity, resulting in lysosomal glycogen accumulation in muscles and irreversible muscle damage.1-3
